The High Court has settled a 16-year battle between the federal government and Sanofi over alleged excess subsidies it paid after a judge blocked the release of a generic version of blood thinner Plavix, saying its job was not to âresurrectâ a dead case.
Insurers have won a challenge to a declaration that engineering firm CIMIC could make claims under policies for costs arising from corruption cases, including a $32 million class action settlement.
The NSW appeals court has clarified the operation of the Uniform Law in the state, finding that insurers offering professional indemnity insurance to legal practitioners must be approved by the state’s Attorney General.
Two Gosford-based smash repair businesses have won an appeal in a dispute with AMA Group over the earn out amount the ASX-list company owed under an October 2018 agreement to purchase the companies for $4.8 million.
A judge has dismissed a franchisee class action against the Hogâs Breath Cafe restaurant chain after the lead applicants failed to hand over $1.23 million in security for costs.
The High Court has agreed to weigh in on a 16-year battle between the federal government and French drug maker Sanofi-Aventis over an allegedly unjustified court order that prevented the release of a generic version of blockbuster blood-thinner Plavix.
Livestock drug company Zoetis has agreed to accept a $2.1 million payout to cover its costs in successfully defending a class action dubbed “totally off the planet” by a judge.
A 16-year battle between the federal government and drug maker Sanofi-Aventis over an allegedly unjustified court order that prevented the release of a generic version of blockbuster blood-thinner Plavix has gone to the High Court.
Drug maker Sanofi-Aventis is not liable for the federal governmentâs losses for excess subsidies paid for the blood-thinner Plavix after an allegedly unjustified court injunction prevented the release of a generic version of the blockbuster drug, an appeals court has found.
Pet and livestock drug company Zoetis, which successfully defended a class action over its horse vaccine Equivac, is pressing forward with its claim against the legal team that ran the unfunded case, seeking to recover $500,000 of its $3.8 million legal bill.